Wednesday, December 22, 2021

Very Brief Blog: McDermott Will & Emery Issues 18 Page Report on "Telehealth Post Pandemic"

McDermott Will and Emery has issued a timely 18 page update on "Medicare Reimbursement of Telehealth" after the pandemic - after the public health emergency (PHE).

Access the new report with email registration here.  Most of the report is in a three-column tabular format, specifying a topic (such as direct supervision rules, or audio-only visit rules), the current state under PHE, and potential changes after the PHE.  Several dozen policy topics like these are summarized.

For those primarily interested in lab industry issues, note that telehealth potentially makes large alterations in the channels and pathways for both routine and specialized lab tests.  E;g. a current article in JAMA by Scott Gottlieb notes,, "Home diagnostic tests will be increasingly coupled with telemedicine visits...This ability to connect at-home diagnostic tests with telemedicine and rapid turnaround of definitive laboratory testing will change infectious disease management." 

See McDermott's home page for digital health law and policy here:

Along a related theme, see the FDA's new guidance on digital health, remote technologies, and clinical trials - here.    

And pair that with Morning Consult's new poll on the final arrival of digital technologies in clinical trials, here, something also stressed by Verily's Amy Abernethy here.  These themes highly relevant to the diagnostics industry; see for example Labcorp acquisition of Covance here and IQVIA-Quest collaborations and separations in the clinical trial space here (and here) and the new Thermo Fisher acquisition of PPD clinical research organization here.

See also an article on Surprise Billing and surprise impact on telemedicine here.